Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fabrazyme in Pediatric Patients With Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patient or legal guardian must provide written informed consent~* Patients must have a clinical diagnosis of Fabry disease and active Fabry disease (clinical signs and symptoms)~* Patients must be at least 7 years of age but no older than 15 years of age at time of enrollment~* Patients must be Tanner Stage ≤ III~* Female patients must have a negative pregnancy test prior to each infusion and use a medically accepted form of contraception throughout the study~Exclusion Criteria:~* Patient has a clinically significant organic disease (with the exception of symptoms relating to Fabry disease) that in the opinion of the investigator would preclude participation in the trial~* Patient has participated in a study employing investigational drug within 30 days of the start of this study~* Patient has received prior treatment with enzyme replacement therapy~* Patient is unable to comply with the clinical protocol

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Fabrazyme (Type: EXPERIMENTAL): 1.0 mg/kg of Fabrazyme given to the patients every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).